Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Receivables - Accured (2023 - 2025)

Prokidney (PROK) has disclosed Receivables - Accured for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Receivables - Accured fell 53.94% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 53.94% year-over-year, with the annual reading at $1.1 million for FY2025, 53.94% down from the prior year.
  • Revenue - Other for Q2 2022 was $337595.0 at Prokidney.
  • The five-year high for Receivables - Accured was $8.1 million in Q2 2023, with the low at $714000.0 in Q3 2023.
  • Average Receivables - Accured over 3 years is $2.8 million, with a median of $1.8 million recorded in 2024.
  • The sharpest move saw Receivables - Accured surged 614.57% in 2024, then plummeted 75.75% in 2025.
  • Over 3 years, Receivables - Accured stood at $1.4 million in 2023, then surged by 77.96% to $2.4 million in 2024, then crashed by 53.94% to $1.1 million in 2025.
  • According to Business Quant data, Receivables - Accured over the past three periods came in at $1.1 million, $1.2 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.